AI Engines For more Details: Perplexity Kagi Labs You
Osteoporosis Prevention: Raloxifene helps prevent osteoporosis by increasing bone density and reducing the risk of fractures, particularly in postmenopausal women at risk of developing osteoporosis.
Osteoporosis Treatment: Raloxifene is used to treat osteoporosis by slowing down bone loss and decreasing the risk of vertebral fractures. It helps maintain bone strength and reduce the risk of fractures in postmenopausal women with osteoporosis.
Breast Cancer Risk Reduction: Raloxifene has been shown to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of developing breast cancer. It works by blocking estrogen receptors in breast tissue, thereby inhibiting the growth of estrogen-sensitive tumors.
Cardiovascular Health: Raloxifene may have beneficial effects on cardiovascular health by improving lipid profiles and reducing the risk of cardiovascular events, particularly in postmenopausal women. It has been shown to decrease levels of LDL cholesterol and triglycerides while increasing levels of HDL cholesterol.
Endometrial Cancer: Unlike estrogen-based hormone replacement therapy, raloxifene does not increase the risk of endometrial cancer. In fact, it may have a protective effect against endometrial cancer due to its selective estrogen receptor modulation.
Vasomotor Symptoms: Raloxifene may help alleviate vasomotor symptoms such as hot flashes and night sweats in postmenopausal women, although it is not as effective as estrogen therapy for this purpose.
Uterine Health: Raloxifene does not stimulate the proliferation of the uterine lining (endometrium) like estrogen does, reducing the risk of endometrial hyperplasia and uterine cancer.
Bone Health in Breast Cancer Survivors: Raloxifene may be used to improve bone health in postmenopausal women who are breast cancer survivors and at risk of osteoporosis due to cancer treatments such as aromatase inhibitors or chemotherapy-induced ovarian suppression.
Overall Quality of Life: Raloxifene therapy may contribute to the overall quality of life in postmenopausal women by reducing the risk of fractures, breast cancer, and cardiovascular events, while also potentially alleviating vasomotor symptoms.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 2.8 | 0 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 0.1 | 16 |
| Allergies | 0.3 | 0.4 | -0.33 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.6 | 2.9 | -3.83 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.8 | |
| Ankylosing spondylitis | 0.6 | 1.2 | -1 |
| Anorexia Nervosa | 0.3 | 1.4 | -3.67 |
| Antiphospholipid syndrome (APS) | 1.9 | 1.9 | |
| Asthma | 0.3 | 0.6 | -1 |
| Atherosclerosis | 0 | 2.1 | 0 |
| Atrial fibrillation | 1.3 | 0.6 | 1.17 |
| Autism | 3.5 | 3 | 0.17 |
| Barrett esophagus cancer | 0 | 0.2 | 0 |
| Bipolar Disorder | 0.5 | 0.3 | 0.67 |
| Brain Trauma | 0 | 0.6 | 0 |
| Carcinoma | 1.1 | 0.8 | 0.38 |
| Celiac Disease | 1 | 0.9 | 0.11 |
| Cerebral Palsy | 0.6 | 0.6 | 0 |
| Chronic Fatigue Syndrome | 3.6 | 2.4 | 0.5 |
| Chronic Kidney Disease | 1.4 | 1.2 | 0.17 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.4 | 1.5 |
| Chronic Urticaria (Hives) | 0.5 | 0.3 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.5 | 0 |
| Colorectal Cancer | 1.7 | 0.4 | 3.25 |
| Constipation | 0.5 | 0.3 | 0.67 |
| Coronary artery disease | 1.3 | 0 | 0 |
| COVID-19 | 4.4 | 6.5 | -0.48 |
| Crohn's Disease | 3.7 | 2.5 | 0.48 |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.5 | -0.5 | |
| Depression | 5.3 | 4 | 0.32 |
| Dermatomyositis | 0.2 | 0 | 0 |
| Eczema | 0.9 | 1.1 | -0.22 |
| Endometriosis | 0.8 | 0.4 | 1 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.8 | 1.2 | -0.5 |
| Fibromyalgia | 1.5 | 1.7 | -0.13 |
| Functional constipation / chronic idiopathic constipation | 2.7 | 1.5 | 0.8 |
| gallstone disease (gsd) | 0.6 | 0.3 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.2 | 1.5 |
| Generalized anxiety disorder | 0.9 | 0.7 | 0.29 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 0 | 0 | |
| Graves' disease | 0.6 | 0.3 | 1 |
| Halitosis | 0.3 | 0.2 | 0.5 |
| Hashimoto's thyroiditis | 0.6 | 0.3 | 1 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.8 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 0.6 | -0.6 | |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.8 | 1.8 | -1.25 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 3.6 | -3.6 | |
| Inflammatory Bowel Disease | 1.9 | 3.8 | -1 |
| Insomnia | 0.5 | 0.6 | -0.2 |
| Intelligence | 1.4 | 1.4 | |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 1.9 | 2.6 | -0.37 |
| Liver Cirrhosis | 1.7 | 1.2 | 0.42 |
| Long COVID | 3.7 | 2.7 | 0.37 |
| Low bone mineral density | 0.4 | -0.4 | |
| Lung Cancer | 0.2 | 0.2 | |
| ME/CFS with IBS | 0.5 | 0.4 | 0.25 |
| ME/CFS without IBS | 1.5 | 0.7 | 1.14 |
| Menopause | 0.5 | 0.5 | |
| Metabolic Syndrome | 3.1 | 3.6 | -0.16 |
| Mood Disorders | 5.9 | 4 | 0.48 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 1.3 | 3.6 | -1.77 |
| Multiple system atrophy (MSA) | 1 | 0 | 0 |
| Neuropathy (all types) | 0.2 | 0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 1.5 | -2 |
| NonCeliac Gluten Sensitivity | 0 | 0 | |
| Obesity | 3.4 | 1.8 | 0.89 |
| obsessive-compulsive disorder | 2.7 | 1.9 | 0.42 |
| Osteoarthritis | 1.7 | 1.7 | |
| Osteoporosis | 0.6 | 0.3 | 1 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 0.5 | 2.2 | -3.4 |
| Polycystic ovary syndrome | 1 | 0.9 | 0.11 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.1 | 2 |
| Premenstrual dysphoric disorder | 0 | 0.3 | 0 |
| primary biliary cholangitis | 1 | -1 | |
| Psoriasis | 0.9 | 1.2 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 1.6 | 0.31 |
| Rosacea | 0 | 0.6 | 0 |
| Schizophrenia | 3 | 0.7 | 3.29 |
| scoliosis | 0 | 0.1 | 0 |
| Sjögren syndrome | 0.7 | 2 | -1.86 |
| Sleep Apnea | 0.1 | 0.6 | -5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 1.2 | 0.6 | 1 |
| Systemic Lupus Erythematosus | 2.3 | 0.7 | 2.29 |
| Tic Disorder | 0.5 | 0 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.3 | 1.1 | 0.18 |
| Type 2 Diabetes | 3 | 3.8 | -0.27 |
| Ulcerative colitis | 1.2 | 3.1 | -1.58 |
| Unhealthy Ageing | 1.9 | 1.5 | 0.27 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.